|
|
Blood, 15 October 2003, Vol. 102, No. 8, pp. 3016-3024.
Prepublished online as a Blood First Edition Paper on July 10, 2003; DOI 10.1182/blood-2002-09-2972.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to Bryostatin 1
Traci E. Battle, and
David A. Frank
From the Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Bryostatin 1 is known to exhibit in vitro and in vivo activity against chronic lymphocytic leukemia (CLL) cells by inducing their further maturation into plasmalike cells. Signal transducer and activator of transcription (STAT) proteins play a central role in B-lymphocyte growth and function and are aberrantly phosphorylated on serine residues in CLL cells. To determine whether STAT transcription factors are important in Bryostatin 1–induced differentiation of CLL cells, primary CLL cells were examined for signaling events following exposure to Bryostatin 1 in vitro. Western analysis and electrophoretic mobility shift assays revealed that Bryostatin 1 induced tyrosine phosphorylation and DNA binding of STAT1, yet there was no effect on constitutive serine phosphorylation of STAT1. Bryostatin 1–induced STAT1 activation occurred in a manner that was dependent on protein kinase C (PKC), mitogen-activated protein kinase (MAPK), and Janus tyrosine kinase (JAK) activation. Evidence indicates that Bryostatin 1 induces STAT1 activation through an interferon  (IFN) autocrine loop. However, STAT1 activation by IFN stimulation alone was not sufficient to induce differentiation. This insufficiency is due to the broader effect on gene expression caused by Bryostatin 1 compared with IFN, as demonstrated by microarray analysis. Both up-regulation of CD22 expression and immunoglobulin M (IgM) production, markers of CLL differentiation, were inhibited by a decoy oligonucleotide for STAT1, indicating that STAT1 is necessary for Bryostatin 1–induced differentiation of CLL cells. This study implicates STAT transcription factors as important mediators of Bryostatin 1–induced differentiation of CLL cells and could possibly lead to improved therapeutic approaches for the treatment of CLL.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. Germain and D. A. Frank
Targeting the Cytoplasmic and Nuclear Functions of Signal Transducers and Activators of Transcription 3 for Cancer Therapy
Clin. Cancer Res.,
October 1, 2007;
13(19):
5665 - 5669.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Lynch, J. Etchin, T. E. Battle, and D. A. Frank
A Small-Molecule Enhancer of Signal Transducer and Activator of Transcription 1 Transcriptional Activity Accentuates the Antiproliferative Effects of IFN-{gamma} in Human Cancer Cells
Cancer Res.,
February 1, 2007;
67(3):
1254 - 1261.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Battle, R. A. Lynch, and D. A. Frank
Signal transducer and activator of transcription 1 activation in endothelial cells is a negative regulator of angiogenesis.
Cancer Res.,
April 1, 2006;
66(7):
3649 - 3657.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. V. Alvarez, H. Greulich, W. R. Sellers, M. Meyerson, and D. A. Frank
Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.
Cancer Res.,
March 15, 2006;
66(6):
3162 - 3168.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Tomic, D. White, Y. Shi, J. Mena, C. Hammond, L. He, R. L. Miller, and D. E. Spaner
Sensitization of IL-2 Signaling through TLR-7 Enhances B Lymphoma Cell Immunogenicity
J. Immunol.,
March 15, 2006;
176(6):
3830 - 3839.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Battle, J. Arbiser, and D. A. Frank
The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells
Blood,
July 15, 2005;
106(2):
690 - 697.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Wojciechowski, H. Li, S. Marshall, C. Dell'Agnola, and I. Espinoza-Delgado
Enhanced Expression of CD20 in Human Tumor B Cells Is Controlled through ERK-Dependent Mechanisms
J. Immunol.,
June 15, 2005;
174(12):
7859 - 7868.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Nelson, S. R. Walker, J. V. Alvarez, and D. A. Frank
Isolation of Unique STAT5 Targets by Chromatin Immunoprecipitation-based Gene Identification
J. Biol. Chem.,
December 24, 2004;
279(52):
54724 - 54730.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Yuan, F. J. Liddle, S. Mahajan, and D. A. Frank
IL-6-induced survival of colorectal carcinoma cells is inhibited by butyrate through down-regulation of the IL-6 receptor
Carcinogenesis,
November 1, 2004;
25(11):
2247 - 2255.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
